Replies to post #162288 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I hear you. When management writes with not one but two interpretations almost always available to them, while goal posts seem to shift and for some here, dilution is harder to overcome, it is hard to justify averaging down over other priorities. Of course, for those who are able to without sacrifice, it seems a no brainer to avoid letting their stake be diluted until definitive results. It’s a quandry for those who don’t wipe with Benjamins.

[MI Dendream]

Right, right, right.... I gotcha!

But the question is which comes first, the publication or data reporting. Do we get a top line nod before full data release? At ASCO Late Breaker? Later?

My guess is the article in review is timed by XXX journal to realease just a monthish ahead of ASCO. That means a best we get a top lone hit or miss due to ASCO embargoe rules.